A team from The Jackson Laboratory (JAX) and collaborators reported an epigenetic strategy to reactivate a silenced tumor suppressor in acute myeloid leukemia. The approach centers on inhibiting KDM4 enzymes to restore expression of ZBTB7A, reducing leukemia burden in mouse models while reportedly leaving normal blood formation largely unaffected. The study used a translational mapping toolkit—FISHnCRISP—combining FISH and flow cytometry with CRISPR editing to pinpoint ZBTB7A as a key gene silenced in AML. In vivo experiments supported the model that AML cells’ longer ZBTB7A regulatory tail recruits ZFP36L2, and that KDM4-driven chromatin packaging keeps the gene shut. The findings add to a crowded AML therapeutics landscape but specifically narrow attention to a defined epigenetic node and a measurable gene reactivation outcome, setting up the next stage of target validation and therapeutic feasibility work.